Nick van Dijk
Research Subjects
Nick van Dijk has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Michiel S. van der Heijden
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
23 shared publications - Jeroen van Dorp
Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands
22 shared publications - Erik Hooijberg
Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Alberto Gil-Jimenez
Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands
14 shared publications - Annegien Broeks
Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands
14 shared publications - Antoine G. van der Heijden
Department of Urology Radboud University Medical Center Nijmegen The Netherlands
14 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
The NABUCCO treatment regimens for cohort 1, 2A and 2B. Cohort 1 was the initial cohort. Later in time, cohort 2 was initiated, in which patients were randomized to cohort 2A (ipilimumab-high) or cohort 2B (ipilimumab-low). Before treatment initiation, tumor tissue was obtained during a transurethral resection of the tumor (lower tract tumors) or via a biopsy (upper tract tumors).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
The NABUCCO treatment regimens for cohort 1, 2A and 2B. Cohort 1 was the initial cohort. Later in time, cohort 2 was initiated, in which patients were randomized to cohort 2A (ipilimumab-high) or cohort 2B (ipilimumab-low). Before treatment initiation, tumor tissue was obtained during a transurethral resection of the tumor (lower tract tumors) or via a biopsy (upper tract tumors).
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Patient fractions per molecular subtype for response groups a. Fraction of patients per molecular subtype (n=5) according to the consensus classification. b. Fraction of patients per molecular subtype (n=4) according to the TCGA classification. There were no neuro-endocrine subtypes in our patient cohort. Responders (<=ypT1N0) are depicted in blue, non-responders (ypT2-4aNx or ypTxN1-3) are depicted in orange.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Patient fractions per molecular subtype for response groups a. Fraction of patients per molecular subtype (n=5) according to the consensus classification. b. Fraction of patients per molecular subtype (n=4) according to the TCGA classification. There were no neuro-endocrine subtypes in our patient cohort. Responders (<=ypT1N0) are depicted in blue, non-responders (ypT2-4aNx or ypTxN1-3) are depicted in orange.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Consort diagram of available samples per analysis for each arm at baseline and on-treatment. One patient in arm 2A and 3 patients in arm 2B did not undergo cystectomy.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Consort diagram of available samples per analysis for each arm at baseline and on-treatment. One patient in arm 2A and 3 patients in arm 2B did not undergo cystectomy.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Details about methods used for mIF, DNA- and RNA isolation and sequencing and single-cell RNA sequencing
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Details about methods used for mIF, DNA- and RNA isolation and sequencing and single-cell RNA sequencing
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Treatment dynamics of CD8+TCF7+ T-cells in two responders to ipilimumab-high. a. Baseline bladder tissue stained with a multiplex immunofluorescence T-cell panel (DAPI (blue), PanCK (white), CD8 (red), TCF7 (yellow)) for responder #1 (ypT0N0) to high-dose ipilimumab plus nivolumab. b. On-treatment resected bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #1 (ypT0N0) to high-dose ipilimumab plus nivolumab; c. Baseline bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #14 (ypT0N0) to high-dose ipilimumab plus nivolumab; d. On-treatment resected bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #14 (ypT0N0) to high-dose ipilimumab plus nivolumab. The on-treatment tissue of both patients was used for single-cell RNA-sequencing to further characterize the CD8+TCF7+ cells.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Treatment dynamics of CD8+TCF7+ T-cells in two responders to ipilimumab-high. a. Baseline bladder tissue stained with a multiplex immunofluorescence T-cell panel (DAPI (blue), PanCK (white), CD8 (red), TCF7 (yellow)) for responder #1 (ypT0N0) to high-dose ipilimumab plus nivolumab. b. On-treatment resected bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #1 (ypT0N0) to high-dose ipilimumab plus nivolumab; c. Baseline bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #14 (ypT0N0) to high-dose ipilimumab plus nivolumab; d. On-treatment resected bladder tissue stained with a multiplex immunofluorescence T-cell panel for responder #14 (ypT0N0) to high-dose ipilimumab plus nivolumab. The on-treatment tissue of both patients was used for single-cell RNA-sequencing to further characterize the CD8+TCF7+ cells.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Mutational analysis DDR genes. Fraction and type of alterations for various DNA damage response genes in responders (blue) and non-responders (orange). The different treatment arms are depicted in light green (arm 1), dark green (arm 2A) and lilac (arm 2B).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Mutational analysis DDR genes. Fraction and type of alterations for various DNA damage response genes in responders (blue) and non-responders (orange). The different treatment arms are depicted in light green (arm 1), dark green (arm 2A) and lilac (arm 2B).
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Baseline expression of TLS-signature for response groups. Average expression of a TLS signature described by Cabrita and colleagues (Nature, 2020) on baseline bulk RNA sequencing samples for responders (blue; ≤ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Baseline expression of TLS-signature for response groups. Average expression of a TLS signature described by Cabrita and colleagues (Nature, 2020) on baseline bulk RNA sequencing samples for responders (blue; ≤ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3).
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
T-cell subsets at baseline between responders and non-responders for ipilimumab-high and ipilimumab-low. a. T-cell densities at baseline for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3) in the ipilimumab-high cohorts (cohort 1+2A); b. T-cell densities at baseline for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3) in the ipilimumab-low cohort (cohort 2B).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
T-cell subsets at baseline between responders and non-responders for ipilimumab-high and ipilimumab-low. a. T-cell densities at baseline for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3) in the ipilimumab-high cohorts (cohort 1+2A); b. T-cell densities at baseline for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3) in the ipilimumab-low cohort (cohort 2B).
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Tumor mutational burden (TMB) in responders vs non-responders for ipilimumab-high and ipilimumab-low. Baseline TMB (somatic non-synonymous TMB per Mb) in the ipilimumab-high cohorts (cohort 1 and 2A; left panel) and the ipilimumab-low cohort (cohort 2B; right panel) for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3).
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Tumor mutational burden (TMB) in responders vs non-responders for ipilimumab-high and ipilimumab-low. Baseline TMB (somatic non-synonymous TMB per Mb) in the ipilimumab-high cohorts (cohort 1 and 2A; left panel) and the ipilimumab-low cohort (cohort 2B; right panel) for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3).